Vanguard Global Advisers
CNTX icon

Vanguard Global Advisers’s Context Therapeutics CNTX Stock Holding History

Vanguard Global Advisers’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.99K Hold
12,612
– – ﹤0.01% 3526
2026
Q1 		$33K Buy
+12,612
New +$29.5K ﹤0.01% 3171

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Global Advisers's CNTX Position: Q2 2026 in Review

Vanguard Global Advisers held its Context Therapeutics (CNTX) position steady in Q2 2026 at 12,612 shares worth $6.99K. The position accounts for ﹤0.01% of the portfolio, ranked #3526.

Vanguard Global Advisers first reported a position in CNTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $33K in Q1 2026. 75 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • Vanguard Global Advisers held 12,612 shares of Context Therapeutics worth $6.99K as of Q2 2026.
  • Vanguard Global Advisers left its Context Therapeutics share count unchanged in Q2 2026.
  • Context Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3526 holding.
  • Vanguard Global Advisers first reported a position in Context Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Context Therapeutics position peaked at $33K in Q1 2026.
  • 75 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.